UCBJF:OTC-UCB SA (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 106.90

Change

0.00 (0.00)%

Market Cap

USD 19.93B

Volume

101.00

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases in the United States, Europe, and internationally. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; and Nayzilam, a nasal spray rescue treatment for seizure clusters. It also provides Zyrtec and Xyzal for allergies; Nootropil for memory problems; and Xyrem for narcolepsy. In addition, the company offers Evenity for the treatment of osteoporosis; bimekizumab for treating psoriasis, psoriatic arthritis, and axial spondyloarthritis; and dapirolizumab pegol for systemic lupus erythematosus. Further, it is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; UCB7858 for immunology; and UCB0599 for neurology; and UCB0107 for progressive supranuclear palsy. Additionally, the company engages in contract manufacturing activities. It has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company was founded in 1928 and is headquartered in Brussels, Belgium.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

N/A

USD167.99B 29.71 2.87
CSLLY CSL Limited

N/A

USD96.16B 46.11 26.33
CMXHF CSL Limited

N/A

USD94.62B 45.29 26.33
GNMSF Genmab A/S

N/A

USD28.04B 121.29 3.24
UCBJY UCB SA

N/A

USD19.87B 19.75 17.47
SBMFF Sino Biopharmaceutical Limited

N/A

USD19.71B 31.21 2.97
SBHMY Sino Biopharmaceutical Limited

N/A

USD19.71B 28.00 2.97
PPTDF PeptiDream Inc

N/A

USD7.19B 260.99 1.65
IDRSF Idorsia Ltd

N/A

USD5.36B 130.60 N/A
ABCZF Abcam plc

N/A

USD5.21B 57.64 114.95

ETFs Containing UCBJF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.56% 27% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.56% 27% F 33% F
Trailing 12 Months  
Capital Gain 23.09% 49% F 58% F
Dividend Return 1.43% 90% A- 28% F
Total Return 24.51% 49% F 58% F
Trailing 5 Years  
Capital Gain 25.34% 61% D- 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.34% 60% D- 48% F
Average Annual (5 Year Horizon)  
Capital Gain 10.37% 47% F 59% F
Dividend Return 1.44% 89% B+ 37% F
Total Return 11.80% 48% F 58% F
Risk Return Profile  
Volatility (Standard Deviation) 21.19% 93% A 72% C-
Risk Adjusted Return 55.69% 87% B+ 85% B
Market Capitalization 19.93B 98% A+ 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 19.80 44% F 38% F
Price/Book Ratio 2.31 73% C 41% F
Price / Cash Flow Ratio 22.60 8% F 9% F
EV/EBITDA 17.47 35% F 21% F
Management Effectiveness  
Return on Equity 11.33% 87% B+ 78% C+
Return on Invested Capital 11.64% 63% D 73% C
Return on Assets 6.02% 94% A 88% B+
Debt to Equity Ratio 12.98% 39% F 66% D
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.44 64% D 70% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.